Breast cancer accounts for 31% of all cancers diagnosed in Indian women, making it the leading type of cancer. This serious disease must be treated at an early stage for the best outcomes. Our blog breaks down the breast cancer t..
Marec 2023: Abemaciclib (Verzenio, Eli Lilly and Company) in endokrino terapijo (tamoksifen ali zaviralec aromataze) je odobrila Uprava za hrano in zdravila (FDA) za adjuvantno zdravljenje odraslih bolnikov z ..
Feb 2023: Enhertu (trastuzumab deruxtecan) from AstraZeneca and Daiichi Sankyo has been approved as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ..
Februar 2023: Hamsa Nandini, ki so ji leta 2021 diagnosticirali invazivni karcinom stopnje III (rak dojke), je svojim sledilcem na Instagramu sporočila svoje zdravstveno stanje. Igralka, ki je nastopila v teluških filmih, kot sta Mirchi in Lege..
Feb 2023: The Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for people with hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cance..
In February 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for women or men over 50 who have advanced or metastatic breast cancer and are ER-positive, HER2-negative, and h..
April 2022: Odrasli bolniki z neresektabilnim ali metastatskim HER2-pozitivnim rakom dojke, ki so prejeli predhodno zdravljenje na osnovi anti-HER2 bodisi v okolju z metastazami bodisi v neoadjuvantnem ali adjuvantnem okolju in so razvili.
Marec 2022: Uprava za hrano in zdravila je odobrila olaparib (Lynparza, AstraZeneca Pharmaceuticals, LP) za adjuvantno zdravljenje odraslih bolnikov s škodljivo ali sumljivo škodljivo zarodno linijo z mutiranim BRCA (gBRCAm) h..
Oktober 2021: Uprava za hrano in zdravila je odobrila abemaciklib (Verzenio, Eli Lilly and Company) v kombinaciji z endokrino terapijo (tamoksifen ali zaviralec aromataze) za adjuvantno zdravljenje odraslih bolnikov s ho..
Avgust 2021: FDA je odobrila pembrolizumab (Keytruda, Merck) za visoko tvegan, trojno negativen rak dojke v zgodnji fazi (TNBC) kot neoadjuvantno zdravljenje v kombinaciji s kemoterapijo, kasneje pa kot samostojno zdravilo kot adjuvans.